AQUARIUS SURGICAL TECHNOLOGIES REPORTS RESULTS OF OPERATIONS FOR THE YEAR ENDING MARCH 31, 2018

Toronto, Ontario, August 10, 2018; AQUARIUS SURGICAL TECHNOLOGIES INC. (ASTI – CSE) ("the Corporation") today reports the results of operations for the three month and twelve month periods ended March 31, 2018. All amounts referenced herein are in Canadian dollars.

The following table shows the results for the comparable periods:

Aquarius Surgical Technologies Inc.
(formerly Aquarius Coatings Inc.)
Consolidated Statements of Comprehensive Loss
(Expressed in Canadian dollars)

	Three Months Ended		Year Ended	
	Mar 31, 2018	Mar 31, 2017	Mar 31, 2018	Mar 31, 2017
	\$	\$	\$	\$
Sales	420,848	5,895	974,538	5,895
Cost of sales (Note 6)	344,481	5,684	863,472	5,684
Gross Margin	76,368	211	111,066	211
Expenses				
General and administrative	468,643	768,170	1,538,886	843,216
Impairment of goodwill and intangibles	5,759,110	-	5,759,110	-
Bank charges and interest	2,650	976	9,530	2,530
Amortization	123,443	40,080	491,100	40,150
	6,353,846	809,226	7,798,626	885,896
Net loss before other items	(6,277,479)	(809,015)	(7,687,560)	(885,685)
Other items:				
Fair value change in Series "A" special shares	282,978	=	282,978	-
Royalty income	-	1,158	2,592	9,377
Net income (loss) before taxes	(5,994,501)	(807,857)	(7,401,990)	(876,308)
Provision for tax recovery	1,150,100	-	1,150,100	
Net income (loss) after taxes	(4,844,401)	(807,857)	(6,251,890)	(876,308)
Loss per share, basic and diluted	(\$0.27)	(\$0.11)	(\$0.35)	(\$0.14)
Weighted average number of shares outstanding	18,233,545	7,514,709	17,881,405	6,473,796

Management of the Corporation determined that it was not possible to demonstrate the measurable value of Exclusive Distributorship Agreements with manufacturers in Europe; this resulted in Management's decision to recognize an impairment of goodwill and intangibles in the amount of \$5,759,110 and an adjustment of \$282,978 in the fair value of the Series "A" special shares.

Excluding the above noted items the loss before taxes was for the year ended March 31, 2018 was \$1,925,858 (\$0.11 per share) compared to a loss of \$876,308 (\$0.14 per share) in the prior year.

The results in the current year include the operations of Surgical Lasers Inc. which was acquired effective from March 1, 2017. The per share amounts for the prior year have been adjusted to reflect the consolidation of the Corporations shares on a 1 for 20 basis effective February 24, 2017

The Corporation has filed its audited consolidated financial statements and management discussion and analysis for the year ended March 31, 2018. Both are available under the Corporation's profile on SEDAR at www.sedar.com. These and other corporate filings are also available on the CSE website www.thecse.com under the Corporation's symbol "ASTI".

For further information, please contact:

N Gary Van Nest Acting Chief Executive Officer (647) 308-0685 Email: gary@sinaltainvestments.com

The Canadian Securities Exchange has neither approved nor disapproved of the information contained in this release. This Media Release may contain forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ from those projected herein and depend on a number of factors including the success of the Corporation's sales strategies.